LDL-cholesterol targets: lower is better, no matter what method Meeting report 02 February 2013 Pages: 3 - 4
Adverse events: significant cost impact in renal transplant Clinical study 02 February 2013 Pages: 5 - 5
Quick-release bromocriptine promising new treatment for T2DM Clinical study 02 February 2013 Pages: 5 - 5
Dronabidol/cannabidiol shows long-term efficacy in MS pain Media release 02 February 2013 Pages: 6 - 6
FX 06 fails to FIRE as adjunct treatment for acute STEMI Clinical study 02 February 2013 Pages: 6 - 6
Aclidinium bromide a breath of fresh air for patients with COPD Media release 02 February 2013 Pages: 7 - 7
R 7128 reduces HCV RNA levels in patients with hepatitis C Media release 02 February 2013 Pages: 8 - 8
IC 41 vaccine programme encouraging for patients with hep C Media release 02 February 2013 Pages: 9 - 9
Cardiac care heavily influenced by local, national culture Clinical study 02 February 2013 Pages: 10 - 10
Cardiometabolic risk factors in T2DM improved by rimonabant Clinical study 02 February 2013 Pages: 12 - 12
Immediate angioplasty for MI continues to impress in CARESS Clinical study 02 February 2013 Pages: 12 - 12
2008 ESC Congress: guidelines for PE, HF and STEMI updated Meeting report 02 February 2013 Pages: 13 - 13
Low-dose aspirin does not prevent cognitive function decline News item 02 February 2013 Pages: 15 - 15
Ciclosporin: renal cysts after paediatric liver transplant Clinical study 02 February 2013 Pages: 16 - 16
Autism group challenges findings of CDC study of MMR vaccine and autism Media release 02 February 2013 Pages: 17 - 17
Ezetimibe and cancer: stormy SEAS calmed by fresh analysis? Meeting report 02 February 2013 Pages: 17 - 17
Alitretinoin receives first marketing authorisation in the UK. Media release 02 February 2013 Pages: 18 - 18
Lacosamide first therapy for partial-onset epilepsy in 3 years Media release 02 February 2013 Pages: 18 - 18
NT 501 gets fast tracked for ocular disorders in the US. Media release 02 February 2013 Pages: 18 - 18
Orphan drug status awarded to cytarabine/daunorubicin in US. Media release 02 February 2013 Pages: 18 - 18